SMN1 and pulmonary arterial hypertension: Anti-SMN antibody-positive patients with RMDs exhibit a higher prevalence of ILD, PAH, myositis, and SSc-related symptoms compared with anti-SMN antibody-negative patients [8, 9, 26].